TELA Bio announced the commercial launch of its NIVIS Fibrillar Collagen Pack. NIVIS Fibrillar Collagen Pack is an absorbent matrix of Type I and Type III bovine collagen designed to manage moderately to heavily exudating wounds and to control minor bleeding. In April 2022, TELA Bio entered an exclusive development and distribution partnership for Collagen Matrix’s proprietary fibrillar collagen pack in the USA. "The commercial launch of NIVIS is a meaningful step forward in our commitment to provide a suite of effective soft tissue repair solutions for our growing customer base in general, and plastics and reconstructive surgery," said Antony Koblish, President and CEO of TELA Bio. "NIVIS is a high-quality product that complements our OviTex portfolio perfectly and provides a new vehicle of growth for the company."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TELA:
- TELA Bio to Participate in the 41st Annual J.P. Morgan Healthcare Conference
- Tela Bio to participate in a conference call with Lake Street
- TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Eight new option listings and one option delisting on November 30th
- TELA Bio to Participate in Piper Sandler 34th Annual Healthcare Conference
